RNAi Consortium In Its Third Phase, the RNAi Consortium Looks to ncRNAs, Gene Over-Expression Premium Despite its relatively low profile since it kicked off its third phase last spring, the Broad Institute's RNAi Consortium is proceeding apace, although its mission has expanded beyond its initial focus of just RNAi. RNAi Consortium Researchers Publish Details of Human ORF Collection Premium The publication comes as the RNAi Consortium looks to expand its work beyond gene silencing to include gain-of-function research. Broad's RNAi Consortium Plans Expansion into ncRNAs for Third Phase Premium While the exact goals of the so-called TRC3 have yet to be defined, the initiative expects that these will include the expansion of its scope to include reagents targeting non-coding RNAs. Breaking News Guardant Health Nabs FDA Approval for Liquid Biopsy CDx With Menarini Breast Cancer Drug Top Five Articles on GenomeWeb Last Week: Guardant Health Layoffs, Ultima Genomics Use, More New Products Posted to GenomeWeb: Qiagen, Thermo Fisher, Bionano Genomics, BillionToOne, More People in the News at Illumina Ventures, Element Biosciences, Epigenomics, Exagen, More Genomic Approaches Boost Rare Disease Diagnoses in Middle Eastern Patient Population The Scan Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups. Genome-Wide Analysis Sheds Light on Genetics of ADHD A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder. MicroRNA Cotargeting Linked to Lupus A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus. Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.